MIGUEL JOSE
MARTIN JIMÉNEZ
Profesor emérito
Ana
Lluch Hernández
Publicaciones en las que colabora con Ana Lluch Hernández (39)
2023
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428
-
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400
2020
-
Association between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women with Breast Cancer
JAMA Dermatology, Vol. 156, Núm. 9, pp. 987-991
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Reply to Y. Usui et al
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 18, pp. 2113-2114
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement
Oncologist, Vol. 24, Núm. 5, pp. 603-611
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2018
-
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)
Breast Cancer Research and Treatment
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634
-
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
-
Physical activity and breast cancer risk by pathological subtype
Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585
2016
-
Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity
Journal of the Academy of Nutrition and Dietetics, Vol. 116, Núm. 12, pp. 1914-1924.e6
-
Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
Critical Reviews in Oncology/Hematology, Vol. 97, pp. 96-106
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study
PLoS ONE, Vol. 10, Núm. 5
-
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis
Oncologist, Vol. 20, Núm. 2, pp. 111-112